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MaOverweight and obesity have reached epidemic levels in the United States and worldwide, and this has contributed to
substantial cardiovascular and other health risks. However, controversy exists concerning the causes of obesity and
effective modalities for its prevention and treatment. There is also controversy related to the concept of metabolically
healthy obesity phenotype, the “obesity paradox,” and on the importance of fitness to protect individuals who are
overweight or obese from cardiovascular diseases. In this state-of-the-art review, the authors focus on “healthy weight”
with the emphasis on the pathophysiologic effects of weight gain on the cardiovascular system; mechanistic/triggering
factors; and the role of preventive actions through personal, education/environment, and societal/authoritative factors,
as well as factors to provide guidance for caregivers of health promotion. Additionally, the authors briefly review
metabolically healthy obesity, the obesity paradox, and issues beyond lifestyle consideration for weight loss with medica-
tions and bariatric surgery. (J Am Coll Cardiol 2018;72:1506–31) © 2018 by the American College of Cardiology Foundation.O verweight and obesity have reachedepidemic levels in the United States andworldwide, affecting nearly three-fourths
of adults in the United States (1,2). In 2016, the prev-
alence of obesity on the basis of body mass index
(BMI) $30 kg/m2 was 39.6% in the U.S. adults, and
the prevalence of Class III obesity (BMI $40 kg/m2)
was 7.7% (3). Obesity is also among the largest health
care costs in the United States, from 147 billion to
nearly 210 billion dollars per year (4). In addition,
obesity is associated with other costs, including
reduced job production, costing employees over
$500 per obese worker per year (5,6). Clearly, obesity
has many adverse effects on health, particularly
on cardiovascular disease (CVD) risk factors and
CVD prevalence and severity (1). More discerning isN 0735-1097/$36.00
m the aJohn Ochsner Heart and Vascular Institute, Ochsner Clinical Schoo
w Orleans, Louisiana; bDepartment of Physical Therapy, College of Appli
icago, Illinois; cPROFITH “PROmoting FITness and Health through Physic
ucation and Sports, Faculty of Sport Sciences, University of Granada, Gr
iversity of Missouri School of Medicine, Columbia, Missouri; and the eNo
icago, Illinois. Dr. Ortega receives support for research activity from the Sp
DER (DEP2016-79512-R); additional funding from the University of Gran
ions: Unit of Excellence on Exercise and Health (UCEES); and the Europ
gramme under grant agreement No. 667302. Dr. Kushner has served on th
d Retrofit. All other authors have reported that they have no relationship
nuscript received February 15, 2018; revised manuscript received Augustthat obesity independently increases risk for
almost all of the CVD risk factors, including hyperten-
sion (HTN), dyslipidemia, glucose abnormalities,
including metabolic syndrome (MetS) and type 2
diabetes mellitus (T2DM), as well as levels of inflam-
mation. Consequently, almost all CVD is increased
in obesity, especially heart failure (HF) (7), but also
HTN, coronary heart disease (CHD), atrial fibrillation
(AF), as well as most other CVD (1,2,7,8).
Typically, normal weight is defined by BMI of
18.5 to 24.9 kg/m2, but there remains considerable
controversy on the impact of various other measures
of body composition/adiposity, including body fat
(BF), waist circumference (WC), waist-to-hip ratio,
and lean mass. Although BMI $30 kg/m2 represents
obesity in U.S. Caucasians and African Americans,https://doi.org/10.1016/j.jacc.2018.08.1037
l—The University of Queensland School of Medicine,
ed Health Science, University of Illinois at Chicago,
al Activity” Research Group, Department of Physical
anada, Spain; dDivision of Cardiovascular Medicine,
rthwestern University, Feinberg School of Medicine,
anish Ministry of Economy and Competitiveness and
ada, Plan Propio de Investigación 2016, Excellence
ean Union’s Horizon 2020 research and innovation
e advisory board for Novo Nordisk, Weight Watchers,
s relevant to the contents of this paper to disclose.
7, 2018, accepted August 8, 2018.
AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial fibrillation
AHA = American Heart
Association
BF = body fat
BMI = body mass index
CHD = coronary heart disease
CO = cardiac output
CRF = cardiorespiratory fitness
CV = cardiovascular
CVD = cardiovascular disease
DASH = Dietary Approaches to
Stop Hypertension
GI = glycemic index
HF = heart failure
HLM = healthy living medicine
HLP = Healthy Living
Practitioner
HTN = hypertension
LV = left ventricle
LVH = left ventricular
hypertrophy
MetS = metabolic syndrome
METs = metabolic equivalents
MHNW = metabolically
healthy normal weight




OSA = obstructive sleep apnea
PA = physical activity
SSB = sugar sweetened
beverages
T2DM = type 2 diabetes
mellitus
WC = waist circumference
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1507values $25 kg/m2 generally represent obesity in
Asians, Middle Eastern, and Mediterranean pop-
ulations. At any given BMI, high WC and waist-to-hip
ratio may lead to a further increase in risk (9). A
WC $94 cm in men and $80 cm in women (cutpoints
of 90 cm in men and 80 cm in women in Asian/
Middle East/Mediterranean populations) indicates
increased risk, and values $102 cm in men and
$88 cm in women (corresponding values of 94 cm
in men and 80 cm in women in Asian/Middle East/
Mediterranean populations) are particularly associ-
ated with increased risk of chronic diseases. The
corresponding values for waist-to-hip ratio associated
with substantially increased risk are $0.9 and 0.85
for men and women, respectively. Clearly the impact
of cardiorespiratory fitness (CRF) and the importance
of the metabolically healthy obesity (MHO) pheno-
type, as well as the “obesity paradox,” remain areas
of considerable controversy.
As recently reviewed in the Journal (10), a major
emphasis is making “Health Promotion a Priority”
with an 8-part Focus Seminar series on the behavioral
factors that impact CV health. In this state-of-the-art
review, we focus on “healthy weight” with the
emphasis on the pathophysiologic effects of weight
gain on the CV system; mechanistic/triggering
factors; and the role of preventive actions through
personal, education/environment, and societal/
authoritative factors, as well as factors to provide
guidance for caregivers of health promotion (Central
Illustration). Additionally, we also briefly review
MHO, the obesity paradox, and issues beyond life-




ROLE OF HEMODYNAMIC, MORPHOLOGIC, AND
METABOLIC ALTERATIONS AND EFFECTS ON VEN-
TRICULAR FUNCTION. Obesity is capable of produc-
ing a variety of hemodynamic, neurohormonal, and
metabolic alterations that may adversely affect car-
diac morphology and ventricular function (11–16), as
described in Table 1 and Figure 1. These changes are
most pronounced in severe obesity (Class III,
BMI $40 kg/m2), but may occur to a lesser extent in
mild (Class I, BMI: 30.0 to 34.9 kg/m2) and moderate
(Class II, BMI: 35.0 to 39.9 kg/m2) obesity (11–14).
Obesity-related changes in cardiac structure and
function have also been reported in children and ad-
olescents (11–13). Early studies suggested that
changes in cardiac morphology and ventricular
function associated with obesity are primarilyattributable to hemodynamic alterations (11–
13). However, in recent years, it has become
increasingly clear that various neurohor-
monal and metabolic factors commonly
associated with obesity may also contribute
to cardiac remodeling and abnormal ventric-
ular function. Thus, it is now evident that the
effects of obesity on cardiac performance and
morphology evolve from a complex, multi-
factorial process of adaptation and maladap-
tation to excess fat accumulation.
Most studies assessing hemodynamic al-
terations in individuals with obesity have
described a high cardiac output (CO) state (11–
15). The presence of excessive adipose accu-
mulation in association with increased fat-
free mass, together with a decrease in sys-
temic vascular resistance produce an increase
in circulating blood volume that leads to an
increase in myocardial oxygen consumption
and augmentation of CO. Because heart rate
rises little, if at all with obesity, the elevation
in CO is attributable predominantly to
increased left ventricular (LV) stroke volume.
In this model, augmented CO predisposes to
the development of LV enlargement. Sec-
ondary (eccentric) left ventricular hypertro-
phy (LVH) may occur in part due to increased
LV wall stress. Adequate hypertrophy may
reduce LV wall stress; however, LV diastolic
dysfunction may ensue (11–13). If LVH is
inadequate, LV wall stress will remain
elevated and over time, LV systolic dysfunc-
tion may accompany LV diastolic dysfunction
(11,12). The presence of LV dysfunction (dia-
stolic, systolic, or both) may lead to elevation
of LV end-diastolic pressure, increased left
atrial pressure (and volume), pulmonary
venous hypertension, and increased pulmo-
nary capillary pressure. Clinical manifestations of
left-sided HF may ensue, and in the absence of
comorbidities such as CHD or HTN are most likely to
occur in patients with severe obesity (11–13). The in-
crease in pulmonary capillary pressure is the pre-
dominant cause of pulmonary arterial hypertension
in these patients, facilitated in some cases by severe
hypoxemia from sleep apnea and obesity-induced
hypoventilation (11,12,15). It is not unusual to detect
a diastolic pressure gradient across the pulmonary
vascular bed in patients with severe obesity (11,12).
Pulmonary arterial hypertension may contribute to
the development of right ventricular hypertrophy and
enlargement and an increase in right atrial pressure
and volume (facilitated by high CO) (11,12). This
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A schematic for the management of obesity to optimize long-term prevention and treatment. CVD ¼ cardiovascular disease; PA ¼ physical activity.
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1508sequence of events may lead to right-sided HF
(11,12,14,15). In fact, HF due predominantly or entirely
to obesity, generally severe obesity, is referred to as
obesity cardiomyopathy (11,12). However, the previ-
ously described alterations in cardiac structure and
function may also occur to a lesser extent in those
with mild to moderate obesity (11–14). Such in-
dividuals are often free from HF symptoms.
Studies assessing LV morphology using a variety of
diagnostic techniques have consistently demon-
strated that LV mass is significantly greater in pa-
tients with obesity (all classes) compared with those
who are normal weight (11–13). The aforementioned
pathophysiological model suggests that in patients
with obesity with increased LV mass, eccentric LVH
should predominate. However, evidence is accumu-
lating to indicate that concentric LV remodeling or
LVH occurs more frequently than eccentric LVH in
obese patients with abnormal LV geometry (12,16–18).
A key factor relating to LV geometry is HTN (19,20),which is typically associated with concentric LV
remodeling or LVH (19,20). Messerli et al. (20)
described “dimorphic cardiac adaptation” to obesity
and HTN, a hybrid form of LVH previously referred to
as eccentric-concentric LVH (now classified as a form
of concentric LVH). In this model, LV chamber size is
larger than that observed with pure concentric LVH,
but smaller than that associated with eccentric LVH
(19,20). LV wall thickness in this model is greater than
that of eccentric LVH, but less than that observed
with pure concentric LVH (19,20). It is important to
take into consideration both duration and severity of
obesity and HTN in reference to LV geometry (21). For
example, a patient with long-standing, poorly
controlled HTN and mild obesity might be expected
to develop concentric LVH, whereas a patient with
severe obesity of long duration, but mild or controlled
HTN, might be expected to develop eccentric LVH.
Most, but not all studies, reporting a high prevalence
of concentric LV remodeling or LVH in obese subjects
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LV ¼ left ventricular; RV ¼ right ventricular.
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1509did not exclude patients with HTN or adjust for its
presence. Another important factor in determining LV
geometry may be fat distribution. Neeland et al. (21)
reported the results of a study that showed that
central (visceral) obesity was more commonly asso-
ciated with concentric LV remodeling or LVH,
whereas peripheral obesity was more commonly
associated with eccentric LVH. In their study, central
obesity was also associated with lower CO and higher
systemic vascular resistance, whereas peripheral
obesity was associated with higher CO and lower
systemic vascular resistance (21).
LV diastolic dysfunction has been reported in all
classes of obesity (11–13). In patients with severe
obesity, LV end-diastolic pressure is often elevated at
rest and may increase substantially with exercise (15).
Impairment of LV diastolic filling or relaxation has
been reported in subjects with obesity relative to
normal weight patients using load-dependent
noninvasive diagnostic techniques (11,12). LV dia-
stolic dysfunction occurs commonly in patients with
obesity and LVH, but has also been described in thosewith normal LV mass (11,12). Studies employing tissue
Doppler imaging, a technique thought to be less
dependent on LV loading conditions, have shown
reduced early diastolic mitral annular velocities in
asymptomatic obese subjects, suggesting the pres-
ence of subclinical LV diastolic dysfunction in this
population (11–13).
In the absence of comorbidities, such as CHD, LV
systolic function assessed using LV ejection phase
indices is usually normal or supranormal (11–14). LV
systolic dysfunction has been reported in uncompli-
cated obesity, predominantly in those with long-
standing severe obesity. Even in this population,
severe impairment of LV systolic function is rare and
should elicit a search for other etiologies (11–13).
Studies utilizing tissue Doppler imaging have re-
ported reduced systolic mitral annular velocities in
asymptomatic obese patients, even when LV ejection
phase indices are normal (11–13). More recently,
studies employing LV strain rate imaging have re-
ported reduced global longitudinal strain and in some
cases decreased radial strain in such patients (12,17).
This suggests the presence of subclinical LV systolic
dysfunction in obesity.
In addition to HTN and fat distribution, there are a
variety of other factors that may contribute to the
development of cardiac remodeling and ventricular
dysfunction in obesity (11–13,22–24). These include
insulin resistance with hyperinsulinemia, activation
of the renin-angiotensin-aldosterone system, stimu-
lation of the sympathetic nervous system, hyper-
leptinemia due to leptin resistance, low levels
of adiponectin, myocardial fibrosis, and lipotoxicity
(11–13,23,24). Obesity is commonly associated with
insulin resistance with compensatory hyper-
insulinemia (11,12,23). Insulin resistance is thought to
contribute to the development of LVH by promoting
binding of insulin to insulin-like growth factor 1 re-
ceptors, which are plentiful in myocardium and by
stimulation of the sympathetic nervous system,
resulting in increased afterload (14,23). In animal
models, insulin resistance increases myocardial fatty
acid uptake and creates an imbalance between fatty
acid uptake and oxidation, which causes accumula-
tion of ceramides and other fatty acid intermediates
that impair myocardial function and promote
apoptosis of cardiomyocytes (13,23,24). Obesity is
associated with activation of the renin-angiotensin-
aldosterone system (11,13). Adipocytes are actually
a source of angiotensinogen and angiotensin-
converting enzyme. Activation of this system stimu-
lates sympathetic nervous system activity that
may predispose to HTN and increase afterload in
normotensive persons with obesity (11–13). Volume
FIGURE 1 Obesity and CVD: Proposed Pathophysiology of Obesity Cardiomyopathy
↑ Total and Central
Blood Volume
↑ LV Stroke Volume
↑ Cardiac Output in Most
LV Dilatation in Some

































This diagram shows the central hemodynamic alterations that result from excessive adipose accumulation in severely obese patients and their subsequent effects on
cardiac morphology and ventricular function. Left ventricular (LV) hypertrophy in severe obesity may be eccentric or concentric. Factors influencing LV remodeling and
geometry include severity and duration of obesity; duration and severity of adverse LV loading conditions (particularly hypertension); and, possibly, neurohormonal and
metabolic abnormalities such as increased sympathetic nervous system tone, activation of the renin-angiotensin-aldosterone system, insulin resistance with hyper-
insulinemia, leptin resistance with hyperleptinemia, adiponectin deficiency, lipotoxicity, and lipoapoptosis. These alterations may contribute to the development of
LV failure. LV failure, facilitated by pulmonary arterial hypertension from sleep apnea/obesity hypoventilation, may subsequently lead to right ventricular (RV) failure.
LA ¼ left atrial.
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1511expansion may increase preload in such individuals.
Angiotensin II is a potent growth factor that promotes
myocardial hypertrophy (11–13). Aldosterone stimu-
lates myocardial fibrosis (13,14). These sequelae form
the substrate for the development of LVH and LV
diastolic dysfunction. Obesity is frequently associated
with leptin resistance and hyperleptinemia (11–14). Ani-
mal studies have reported an association between
hyperleptinemia and LVH (11–14). Elevated leptin
levels stimulated matrix metalloproteinase 2, which
increased synthesis of collagen III and IV in human
pediatric myocytes (14). Adiponectin is a car-
dioprotective adipokine (12–15). Obesity is associated
with low adiponectin levels that reduce the activity of
tissue metalloproteinase inhibitors, thus impairing its
antifibrotic effect in obese subjects. Myocardial lip-
otoxicity is characterized by fatty acid and triglycer-
ide accumulation in cardiomyocytes leading to
cellular dysfunction and death and eventually to
myocardial dysfunction (11,12,23,24). The accumula-
tion of fatty acids and triglycerides in these cells
creates an imbalance between uptake and meta-
bolism of these substances (11,12,23,24). Increased
myocardial triglyceride accumulation has been asso-
ciated with LVH in humans and both LVH and LV
dysfunction in genetically obese rats (11,12,16).
Transgenic murine models of lipotoxicity have been
developed involving stimulation or inhibition of
various enzymes or proteins that modulate lipid up-
take or turnover (11,24). Several of these models have
demonstrated LV diastolic and systolic dysfunction.
Cardiac remodeling and myocardial dysfunction
associated with lipotoxicity in animal models are
thought to be mediated by long chain fatty acids and
their metabolic products such as diglycerol or
ceramides (11,12,23,24). As previously noted, this
process has been described with insulin resistance in
animal models (23). Whether lipotoxicity is respon-
sible for the development of LV dysfunction in
humans is uncertain. High levels of tumor necrosis
factor alpha, reactive oxygen species, and C-reactive
protein in adipocytes have stimulated conjecture that
apoptosis, oxidative stress, and inflammation may
play an important role in cardiac remodeling in
obesity, but confirmatory data are lacking (13,14).
BEHAVIORAL CONSEQUENCES OF OBESITY
Even though it is well-established that obesity serves
as a potent risk factor for various cardiometabolic
comorbidities, discussions focusing on obesity’s
relationship to behavioral and psychosocial morbid-
ities, which may otherwise hinder obesity treatment
strategies, have been relatively limited. Concurrentwith the growing global obesity epidemic, there has
been a similar risk in breathing-related sleep disor-
ders, particularly those characterized by the recurrent
collapse of the pharyngeal airway during sleep (25).
Although sleep apnea may result from or be worsened
by obesity, it can also lead to adverse consequences.
Most notable of the subtypes of sleep disorders is
obstructive sleep apnea (OSA), because of its rela-
tionship to various CVD and metabolic comorbidities
(26,27). Whereas sleep disorders are suggested to be
causal in the pathway leading to weight gain, obesity
is considered as the most potent demographic risk
factor for the development and progression of OSA
(25,26). Current estimates posit OSA prevalence rates
of >40% in patients who are overweight, but other-
wise healthy, and nearly 50% to 98% in patients with
severe obesity (BMI $40 kg/m2) (25,27). Physiologi-
cally, obesity’s effect on OSA susceptibility can be
explained, in part, by the differentiating effects of fat
patterning and fat distribution, the inflammatory re-
sponses elicited from these fat depots, and the
anatomic alterations such as excessive adiposity
around the pharynx and chest as well as fat deposited
around the upper airway that predispose to upper
airway obstruction during sleep (27). Notably, the
pathogenic effects of central (visceral) obesity on OSA
development have specifically been shown to increase
mechanical loading in the upper airway, contributing
to airway collapsibility and/or decreased compensa-
tory neuromuscular responses (27). Inherent differ-
ences in fat distribution also explain why OSA
predominates in men versus women (26); whereas
men typically carry greater central fat deposition and
subscapular skin fold thickness (26,27), leading to
increased resistive load of the upper airway, greater
peripheral adiposity in women may be a factor that
protects them from developing OSA (26). Other
studies have shown OSA correlates with neck size,
which also increases with central obesity (25).
Without argument, weight loss is implicated as the
most important and effective component of healthy
living medicine (HLM) (28), with the goal of reversing
an obesity classification and the severity and burden
of its behavioral consequences, including breathing-
related sleep disorders. However, curtailing weight
loss efforts are a host of psychological disorders that
manifest as a consequence of obesity, and therefore
challenge long-term success of weight loss in pop-
ulations with obesity. Theories underlining the health
psychology model suggest weight stigma and inter-
nalization of weight bias are psychological stressors
that beget weight gain/regain by perpetuating
the body’s central stress-response hypothalamic-
pituitary-adrenocortical axis, and activating the
TABLE 2 Proposal of a Harmonized Definition of MHO and MUHO or MUO in Adults
Definition of MHO
Based on the 7 fundamental points and recommendations discussed elsewhere (8) (see Online Table 1 for more detailed information), a person would
be classified as MHO if they are obese (BMI $30 kg/m2) plus they meet 0 of the 4 MetS criteria (WC excluded), which are the following (34):
Elevated triglycerides (Drug treatment for elevated triglycerides is an alternate indicator.*) $150 mg/dl (1.7 mmol/l)
Reduced high-density lipoprotein cholesterol (Drug treatment for reduced HDL-C is an alternate
indicator.*)
<40 mg/dl (1.0 mmol/l) in men
<50 mg/dl (1.3 mmol/l) in women
Elevated blood pressure (Antihypertensive drug treatment in a patient with a history of hypertension
is an alternate indicator.)
Systolic $130 and/or diastolic
$85 mm Hg
Elevated fasting glucose† (Drug treatment of elevated glucose is an alternate indicator.) $100 mg/dl (5.6 mmol/l)
Definition of MUHO or MUO
A person would be classified as MUHO or MUO if they are obese (BMI $30 kg/m2) plus they meet 1 to 4 of the MetS criteria indicated (WC excluded).
*The most commonly used drugs for elevated triglycerides and reduced HDL-C are fibrates and nicotinic acid. A patient taking 1 of these drugs can be presumed to have high
triglycerides and low HDL-C. High dose of omega-3 fatty acids presumes high triglycerides. †Most patients with type 2 diabetes mellitus will have the MetS by the proposed
criteria.
BMI ¼ body mass index; HDL-C ¼ high-density lipoprotein cholesterol; MetS ¼ metabolic syndrome; MHO ¼ metabolically healthy obesity; MUHO ¼ metabolically unhealthy
obesity; MUO ¼ metabolically unhealthy obesity; WC ¼ waist circumference.
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hypercortisolemia, which promotes central obesity
and is implicated in a myriad of obesity-related
comorbidities (29), is also hypothesized to drive
maladaptive eating behaviors (binge eating, night
eating) (30) by sensitizing the food-reward system.
Hence, increased eating behavior in obesity is often
seen as a response to coping with psychological stress
induced by weight stigma (30). Accordingly, higher
levels of psychological stress are suggested as medi-
ators of anxiety (31) and depression (32) in adults and
possibly in childhood and adolescent obesity (33).
These data together suggest that whereas lifestyle
and behavior modification remains the gold standard
approach to treating obesity, it is imperative that
clinicians understand potential behavioral responses
to obesity and psychological sequelae of obesity that
may undermine weight loss goals and further in-
crease risk of clinical comorbidities. In terms of alle-
viating the medical burdens associated with obesity,
applying a more comprehensive obesity treatment
approach that prioritizes behavioral and psychologi-
cal challenges of obesity is warranted. This multidis-
ciplinary approach may help guide clinicians to
identify patients who are less likely to respond to
traditional lifestyle intervention and provide avenues
for more effective primary, secondary, and tertiary
prevention and treatment strategies.
METABOLICALLY HEALTHY OBESITY
DEFINITION, PREVALENCE, AND CHARACTERISTICS
OF MHO. Defini t ion . MHO is defined as a subset of
individuals who are obese but have otherwise a
totally normal and healthy metabolic profile, that
is, absence of HTN, glucose abnormalities, anddyslipidemia. The discrepancies in the definition of
MHO have hampered comparability among studies
and contributed to the controversy about the prog-
nosis of these individuals. As a step toward the
standardization of the MHO concept, we have
recently proposed a harmonized definition of the
MHO phenotype (Table 2) based on 7 fundamental
points (Online Table 1) (8,34). Probably the most sig-
nificant change in the MHO definition since the ori-
gins of the concept to date has been to move from the
concept of MHO if meeting 0 or 1 MetS criteria (35,36)
to the concept of MHO if meeting 0 MetS criteria, due
to the rationale that a person with HTN or T2DM
cannot be considered “healthy” and, therefore, MHO
should be considered only in the presence of 0 MetS
criteria (8). Large and recent studies (37,38) have used
the 0 criteria/metabolic abnormalities definition (WC
excluded), confirming, therefore, this definition in
the study of MHO. In opposition to MHO, the rest of
individuals with obesity have been named using
different terms (e.g., metabolically abnormal
obesity), yet the term metabolically unhealthy
obesity (MUO) seems to be the most accepted/used in
the last years.
Prevalence . Following the strict definition of
meeting 0 MetS criteria and evaluating the largest
representative studies conducted in Europe (37) and
the United States (35), the prevalence of MHO seems
to range from 12% to 17% of all adults with obesity.
Caleyachetty et al. (38) have recently published the
largest study in this field, including 3.5 million men
and women representative from the United Kingdom
and observed that 68% of the participants with
obesity were MHO (2 of every 3 obese patients). This
markedly higher prevalence of MHO than in the
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1513previous studies is due to the fact that they did not
use blood pressure or glucose/lipids blood cutpoints
(i.e., criteria) from the MetS definition as usually is
done in this field; they used only physician-
diagnosed or -treated T2DM, HTN, and/or dyslipide-
mia. Regardless of the definition used, it is clear that
the MHO is not a rare condition. Therefore, the
prevalences discussed should inform clinicians
that they can expect from one-sixth to two-thirds of
their patients with obesity clinically managed to be
MHO.
Character i s t i cs . A number of physiological and
phenotypic differences between MHO and MUO have
been identified, including lower levels in markers of
inflammation, insulin resistance, visceral adipose
tissue, fatty liver and atherosclerosis in individuals
with MHO compared with individuals with MUO. Our
study using data from the ACLS (Aerobics Center
Longitudinal Study) was the largest study showing
that individuals with MHO have a significantly higher
CRF level than the individuals with MUO, something
that, together with higher physical activity (PA), has
been recognized as a novel characteristic of the MHO
phenotype in later reviews of published reports
(39,40). Recently, a meta-analysis has confirmed that
MHO, compared with MUO, have higher levels of PA,
lower levels of sedentary behavior, and higher levels
of CRF (41).
IMPACT ON CVD. Numerous studies have focused on
this phenotype and have provided conflicting find-
ings about its prognosis, with some studies suggest-
ing that MHO was a benign condition with similar risk
of fatal and nonfatal CVD mortality than metaboli-
cally healthy normal weight (MHNW), and others
supporting the opposite. In spite of this, accumu-
lating evidence overall suggests that individuals with
MHO have a better CVD prognosis than do their MUO
counterparts, but worse than individuals with
MHNW, supporting the notion that obesity, even if
metabolically healthy, has long-term negative con-
sequences on CV health. Along these lines, 5 sys-
tematic reviews and meta-analyses have concluded
that individuals with MHO are at a higher risk of CVD
mortality and morbidity than individuals with MHNW
(42–46). This idea has been further supported by the
recent and powerful study from Caleyachetty et al.
(38) including 3.5 million participants. There is much
agreement (47) that this study, together with previ-
ous meta-analyses, has definitively demonstrated
that individuals with MHO have a higher risk of
overall and specific CVD than MHNW. However,
whether the differences in CVD risk observed be-
tween these 2 phenotypes are due to differences in
adiposity levels (i.e., obesity per se), as assumed byothers (38,47) or are due to the differences in CRF that
exist between these 2 groups of individuals has yet to
be clarified (48).
ROLE OF CRF IN THE CVD PROGNOSIS OF MHO.
Observations that individuals with MHNW have, on
average, higher CRF levels than age-matched in-
dividuals with MHO is clear and well established
(36,39,41,48,49). The question that remains unan-
swered is whether the differences in CVD risk
observed in the individuals with MHO compared with
the individuals with MHNW could be partially or
completely explained by the existing differences in
CRF between these 2 groups (50). Data from the ACLS
was the first and the largest of its kind (>43,000
participants), demonstrating that the CVD prognosis
of individuals with MHO differed depending on
whether CRF was or was not included in the models
as a confounder. Our findings concur with those
observed in the present study by Caleyachetty et al.
(38) and most of the existing publications (42–46);
however, when CRF is included as a covariate in the
models, the differences in the risk of CVD mortality
and nonfatal CVD incidence between individuals with
MHO and MHNW completely disappeared (Figure 2)
(36). These findings suggest that cohort studies on
MHO lacking information on CRF should acknowl-
edge that as a limitation. Caleyachetty et al. (38)
highlights as a limitation another aspect, the fact
that in their study obesity was defined using BMI,
which does not distinguish between fat and lean
mass. Yet this might not be a limitation, because in a
recent study (51), we showed that BMI could be a
similar if not stronger predictor of CVD mortality and
morbidity than BF percentage or fat-mass index (fat
mass expressed in kilograms divided by height
expressed in meters squared) accurately measured
using a gold standard method. Likewise, a study on
MHO prognosis (36) was able to overcome this po-
tential limitation, by testing the same hypothesis
using BMI-defined obesity and BF percentage (accu-
rately measured)-defined obesity, and obtained
identical conclusions (Figure 2).
The notion that CRF may explain differences in
CVD risk observed between MHO and MHNW was also
supported by a systematic review that observed that 6
of the 7 existing studies that controlled for PA or CRF
found no differences between MHO and MHNW in the
risk of nonfatal CVD incidence, and 7 of the 7 studies
found no difference between MHO and MHNW in the
risk of CVD mortality (44). Our group has recently
meta-analyzed the existing publications that have
accounted for the potential confounding effect of PA
and identified 10 unique cohorts (41). Our findings
suggest that MHO individuals, compared with MHNW








































































Model 1: Adjusted for Basic Confounders* Model 2: Model 1 + CRF
Role of cardiorespiratory fitness (CRF) on the cardiovascular disease (CVD) and all-cause prognosis of metabolically healthy obesity (MHO) men and women compared
with metabolically healthy normal-weight (MHNW) or normal-fat (MHNF) men and women from the ACLS (Aerobics Center Longitudinal Study) (N ¼ 43,265 adults).
*Model 1 is adjusted for age, sex, examination year, smoking, alcohol consumption, and parental history of CVD. Nonfatal CVD events include myocardial infarction,
stroke, and coronary revascularization (i.e., bypass, coronary angioplasty); data available in a subsample of 18,430 participants. Reproduced with permission from
Ortega et al. (41). BF% ¼ body fat percentage; BMI ¼ body mass index; Ref. ¼ reference.
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1514individuals, have a 24% to 33% higher risk of all-cause
mortality and CVD mortality/morbidity. This risk was
borderline significant/nonsignificant, independent of
the length of the follow-up and lower than that re-
ported in previous meta-analyses in this topic,
including all type of studies, which could be indi-
cating a modest reduction in the risk estimates as a
consequence of accounting for PA. In addition, our
meta-analysis identified only 1 study (36) that exam-
ined the role of CRF in the prognosis of MHO in-
dividuals; this study suggested that the differences in
the risk of all-cause mortality and CVD mortality/
morbidity between MHO and MHNW are largely
explained by differences in CRF between these 2
phenotypes. Therefore, the main take-home message
from the landmark study by Caleyachetty et al. (38)
and from most of the currently existing evidence
(42–46) that there is no benign obesity should be
taken cautiously, given support from these studies
indicating that CRF, versus obesity per se, explains
the higher risk observed in MHO versus MHNWpopulations (Figure 2) (8,36,41). In addition, there is
consistent evidence supporting that a sizeable subset
of the individuals with obesity can actually have a
moderately to high CRF level, the so-called fat but fit
paradox, which has consistently shown that being fit
counteracts the negative consequences of obesity on
CVD (52,53).
OBESITY PARADOX IN CVD
A detailed discussion of the obesity paradox is
beyond the scope of this review and has been exten-
sively discussed elsewhere (1,2,7,8,53–59), but in
brief, despite the mark adverse effect of obesity to
worsen almost all of the CVD risk factors, especially
HTN, MetS/T2DM, dyslipidemia, and inflammation,
and to increase the prevalence of almost all CVD,
including HTN, HF, CHD, and AF, and almost all other
CVD, studies have demonstrated that overweight and
at least mildly obese individuals have a better short-
and moderate-term prognosis than do thinner
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1515patients with the same CVD. Although this is partic-
ularly present with the high-risk underweight CVD
patients, normal weight patients also tend to have a
worse prognosis then do their heavier counterparts
with the same CVD. Although this has mostly been
shown with BMI assessments of body composition, in
CHD this is also evident with BF percentage and WC
in addition to BMI.
A major factor impacting prognosis in CVD and
strongly influencing the obesity paradox and CHD,
HF, and AF, however, is CRF (1,2,7,8,53–59). In fact, in
CHD (57), and systolic HF (58,59), there is evidence
that the obesity paradox only exists in the low-fit
patients with thin unfit CHD and HF patients having
a particularly poor prognosis. However, in CHD and
systolic HF, those with relatively preserved fitness
(e.g., not in the bottom quintile or tertile for age- and
sex-related CRF), prognosis is excellent regardless of
the level of body composition. Additionally,
improving CRF and weight loss has been shown to
improve prognosis in patients with AF (56). Although
there is little data on weight loss in CHD or HF on
improving survival, purposeful weight loss is associ-
ated with reductions in CVD events in patients with
CHD (60) and improved symptoms and functional
capacity in HF (2,7). However, in a large recent study
of 3,307 patients (1,038 women) with CHD from Nor-
way who were followed for a median of 15.7 years
(61), we observed no mortality risk reductions with
weight loss and reduced mortality associated with
weight gain among those with normal weight at
baseline. On the other hand, sustained PA was asso-
ciated with substantial mortality reductions (61).
Therefore, PA and exercise training to improve levels
of CRF should be strongly encouraged for patients
with CVD and may be even more important than
weight loss, at least for overweight and mildly obese
CVD patients (1,2,7,8,53–61).
GENETIC FACTORS
Certainly, some individuals have a pre-existing ge-
netic predisposition to excess adiposity (62). Addi-
tionally, genetic factors may not only affect the
development of obesity but may also influence the
location of fat deposition, with some areas of fat
deposition being clearly associated with greater risk
than others (e.g., visceral adipose tissue, epicardial
fat, pericardial fat, and hepatic fat are associated with
higher risk than subcutaneous adipose tissue is), but
also genetic factors may influence the risk that
obesity and various fat depots have on the risk of
adverse health consequences, which have been
reviewed in detail elsewhere (62).MECHANISTIC TRIGGERING FACTORS
There is considerable controversy regarding the
fundamental cause of weight gain and the relative
influence of caloric intake and type of calories
consumed versus PA and caloric expenditure.
Although clearly the etiology of obesity depends on
both of these factors, the relative importance of these
factors remains an area of hot debate. Regardless of
this debate, it is generally accepted that increments in
body weight and overall adiposity, at the most
fundamental level, are the result of chronic positive
energy balance (i.e., energy expenditure > energy
intake) (54).
DIETARY CALORIES, REFINED CARBOHYDRATES,
AND ADDED SUGARS. Mounting evidence has sug-
gested that energy and poor dietary choices are
largely, if not completely, responsible for the obesity
epidemic (54,63–65). Although conventional dogma
treats all calories the same (e.g., a calorie is a calorie),
alternative views suggest the quality of diet indirectly
results in obesity. Certainly, in the United States,
there is ample evidence that weight gain and obesity
rates parallel the increasing consumption of refined
carbohydrate intake and, most notably, added sugars,
particularly in the form of sugar sweetened beverages
(SSB) (66,67). Specifically, excess intake of refined
carbohydrates and, especially, added sugar leads to
altered physiology and hormonal imbalance leading
to insulin resistance and leptin resistance, or internal
starvation. Decreased PA/exercise and time spent in
leisure-time PA and behavioral characteristics, such
as increased sedentariness are also known contribu-
tors of excess weight gain (68–70) and further suggest
obesity is solely due to an excessive energy or caloric
intake reference (54,68). The various aspects of time
spent in leisure-time PA and dietary choices,
including SSB, are discussed in more detail next.
PA AND SEDENTARY BEHAVIORS
Leisure time PA represents a relatively small portion
of total time per week, which is much more affected
by occupation-related PA (68) and household man-
agement energy expenditure (69). Recently, we
demonstrated very marked declines in both
occupation-related PA (68) and household manage-
ment (69) energy expenditure during the last 5 de-
cades along with marked increase in sedentary time
and reductions in PA time in mothers during this
period (70). Although these declines were more
marked in women not working outside the home than
in employed women, realizing that currently two-
thirds of women are now employed outside the
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are noted in almost all groups of women during the
last 5 decades. For example, we demonstrated that
currently, the typical woman had a household man-
agement energy expenditure of approximately 1,700
to 1,800 calories per week less than the typical
woman did 5 decades previously. Considering the fact
that generally approximately 100 calories are burned
for each mile traveled by foot, the typical woman or
mother would have to walk/run 17 or 18 more miles
currently to make up for this reduced caloric expen-
diture. These data suggest that reductions in PA and
energy expenditure may largely explain the marked
increased prevalence in obesity noted in recent de-
cades. Additionally, there is considerable evidence
that PA is the major determinant of CRF, a major
factor in prognosis.
Time spent in sedentary behaviors has been
recently proposed as separate construct from PA (71)
and an independent risk factor for a number of
health outcomes, in other words, all-cause mortality,
CVD incidence and mortality, and T2DM incidence
(72). Ekelund et al. (73) observed that the amount of
sitting time was positively related with a higher
mortality risk, yet this increased risk could be coun-
teracted and become nonsignificant when combined
with high levels of PA. However, the increased risk
associated with television watching was not fully
eliminated by high levels of PA (73), suggesting that
this could be a more harmful sedentary behavior than
others. Concerning sedentary behavior and obesity, a
recent meta-analysis observed a 33% higher risk of
overweight or obesity in the highest categories
compared with the lowest categories of sedentary
behavior (74). However, this same meta-analysis and
other recent narrative reviews, systematic reviews,
and meta-analyses agree that the current evidence
regarding the link between sedentary behavior and
obesity, once PA have been controlled for, is limited
and inconclusive (74–77). Further research is certainly
needed in this field.
GENETIC FACTORS. In addition to biological and
behavioral determinants, multiple genetic de-
terminants or correlates of obesity have been identi-
fied to date (77). In fact, genome-wide association
studies have contributed to the identification of over
100 obesity-associated genetic variants, but their
roles in causal processes leading to obesity and its
consequences remain largely unknown. A more
detailed discussion of genetic factors, in addition to
those mentioned herein and in Walley et al. (62), is
beyond the scope of this review and is reviewed in
detail elsewhere (77).PREVENTION AND TREATMENT
BEHAVIORAL FACTORS. Tobacco cessat ion and
weight management . Cigarette smoking and
obesity are noted as being the leading causes of pre-
ventable death in the United States (78), as well as in
developing countries (79). Therefore, it is no surprise
that the combination of smoking and overweight or
obesity status pose substantial public health burden
(80). Whereas current estimates posit significant de-
clines in the global prevalence in tobacco smoking
rates (81) over the last 30 years, obesity rates have
moved in the opposite direction, reaching historically
high levels (80).
At present, there is burgeoning evidence consis-
tently showing an inverse association between
smoking behavior and weight status. Review of
epidemiological and clinical studies suggest that
current smokers, on average, weigh 4 to 5 kg less than
nonsmokers do (78,82,83) and have a lower likelihood
of becoming obese (79). To this degree, the robust
association between smoking cessation and weight
gain is not unfounded (79,82,84). Reports of weight
gain in both clinically treated quitters (81) and quit-
ters derived from population-based cohorts (79)
average 4 to 5 kg, with the greatest increases of
weight gained observed 3 to 12 months after quitting
(79,82,83). Biologically, increases in appetite, a com-
mon side effect of nicotine withdrawal (81) in
conjunction with declines in energy expenditure in
the range of 4% to 16%, are suggested to contribute to
the cessation-related weight gained observed in
former smokers (79). Furthermore, there is some ev-
idence that suggests smoking cessation is positively
associated with abdominal adiposity, as greater ab-
solute WC (85) and larger increases in WC have been
previously reported in former versus current and
never smokers (79,84). It has been suggested that
post-cessation gains in WC are due to greater gains in
subcutaneous fat relative to visceral fat (79,84).
However, additional research is needed to confirm
the effects of smoking cessation on changes in fat
distribution, particularly as it relates to future chronic
disease risk.
Given that weight gain is an unwelcomed but ex-
pected outcome of smoking cessation, a number of
interventions have been designed to promote smok-
ing cessation while simultaneously curtailing weight
gain (86). Such intervention approaches have
included pharmacotherapy, weight management ed-
ucation, cognitive behavior therapy, and lifestyle
recommendations. Among the various smoking
cessation and weight management interventions
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ical efficacy from all intervention types aimed to
jointly affect smoking cessation and weight gain
remained modest yet insufficient. Only exercise in-
terventions showed some promise in attenuating
long-term (i.e., 12 month) post-smoking cessation–
related weight gain, whereas benefits were not
observed at shorter time points (i.e., #6 months) (86).
Other studies have shown that the amount of PA
engaged while smoking, as well as PA performed after
quitting smoking, significantly reduce the magnitude
of weight gained following cessation (79). Nonethe-
less, these data further underscore the need for clin-
ically effective weight management intervention
strategies that can be easily implemented in smoking
cessation programs (86).
Impl i cat ions for a prudent d iet pattern versus
spec ific d ietary components . Treatment of obesity
through various forms of dietary intervention re-
quires achieving a state of negative energy balance
through decreased energy consumption. Whereas
prior nutrition reports have focused on reducing
portion sizes, or isolating or eliminating specific food
groups and/or nutrients, more recent evidence has
suggested that poor dietary quality and excess diet
quantity (e.g., calories) are drivers of energy imbal-
ance and hence, obesity. (87). Thus, recent dietary
recommendations have shifted away from theories
based on single dietary/nutrient components and diet
restriction/elimination tactics and moved toward
empirical evidence examining foods consumed in
combinations and the overall diet composition
consumed by individuals (87). As such, larger
emphasis on dietary patterns have been endorsed by
the Dietary Guidelines for Americans (88) and The
Obesity Society/American Heart Association (AHA)/
American College of Cardiology (89), as they offer the
opportunity to characterize the overall nutritional
density and thus dietary quality of eating behaviors
in a population rather than providing recommenda-
tions about the quantity of calories or macronutrients
to consume (88). With regard to facilitating behav-
ioral counseling, focusing on diet patterns versus
single nutrients or food groups may permit greater
flexibility and smaller, incremental changes in eating
behavior, thereby increasing potential adherence,
patient mindfulness of selecting healthful eating
choices, and overall effectiveness of the diet recom-
mendations (87).
The most well-studied dietary patterns include the
Mediterranean- and Dietary Approaches to Stop Hy-
pertension (DASH)-style diets (88,89), both of which
emphasize plant-based foods (fruits and vegetables,
whole grains, nuts, legumes, seeds), whole grains(cereals, breads, rice, or pasta), low fat dairy, and low
amounts of red meat. With respect to obesity, Medi-
terranean and DASH diet types have been praised for
their effectiveness in safely promoting weight loss
and reducing long-term weight gain (when combined
with energy restriction) (88,90), while consistently
being associated with reduced CVD risk factors and
metabolic outcomes (91,92). Importantly, adoptions
to DASH or Mediterranean-style diets have been
proposed for sociocultural feasibility (87), under-
scoring their generalizability to various populations,
and greater likelihood of either diet pattern to pro-
mote weight loss/maintenance as well as attenuation
of the presumably inevitable weight gain “rebound”
following weight loss success.
Obes i ty t reatment st rategy : Ev idence for
d ietary qua l i ty aggregate qual i ty . In line with
recommendations of healthy dietary patterns,
evidence-informed dietary priorities include adher-
ence to a low energy-dense dietary prescription (88).
Data pooled from 3 population cohort studies in
middle-aged and older adults have consistently
demonstrated that higher consumption of whole
grains, nuts, fruits and vegetables, specifically higher
fiber and lower glycemic index ([GI], i.e., better car-
bohydrate quality) vegetables, and yogurt are each
associated with less weight gain over a 4-year follow-
up (93–95). Coincidently, these findings overlap with
the primary identified dietary components of Medi-
terranean and DASH diet patterns. On the contrary,
increased intake of starchy, higher GI vegetables,
such as corn, peas, and potatoes, is associated with
weight gain in these populations (95). Biological
mechanisms regarding how specific dietary compo-
nents may reduce weight gain are commonly
explained in terms of their effect on hunger and
satiety (96). For example, the satiating properties of
fruits and vegetables and whole grains, for example,
higher water content per volume and fiber content,
may displace the intake of more energy-dense foods
from the diet (96) and reduce energy absorption from
the gastrointestinal tract (97). Additionally, the
higher fiber content and lower GI of these foods may
further moderate energy intake by slowing down
starch digestion or absorption, reducing postprandial
glucose concentrations (98), and in turn, eliciting
lower insulin and glucose responses that favor fat
oxidation and lipolysis rather than its storage (99).
Higher resting energy expenditures during isocaloric
low GI versus low fat feeding following weight loss
have also been reported in adults who are overweight
or obese, suggesting reduced GI diets may be advan-
tageous for sustaining weight loss in this highly
vulnerable population (100).
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gain associated with increased intakes of refined
carbohydrates (93,94), which are often higher in
starches, fats, and added sugars, that are hypothe-
sized to elicit an immediate insulinemic response,
followed by a hypoglycemic period; this combined
effect leads to reduced satiety and increased hunger
signals and may in turn drive overconsumption of
energy-dense foods, increased total caloric intake,
and consequently weight gain over time. Adverse
metabolic consequences imposed by higher intakes of
refined grains and starches reported in overweight
and obese individuals suggests that these highly
palatable, rapidly digested, low GI/low fiber carbo-
hydrates are aggravated by underlying insulin resis-
tance (101) and may further drive obesogenic
pathways (101,102).
ADDED SUGARS. Conventional wisdom posits that
added sugar (i.e., sweeteners added to processed and
prepared foods including those sugars and syrups
added at the table) is a key driver of the obesity
epidemic (103). The most compelling evidence of
added sugars effect on weight gain derives from
studies evaluating consumption of SSB, which ac-
count for almost one-half of the added sugar
consumed in the United States (104) and remains to
be a consistent dietary feature associated with
obesity, T2DM, and CVD rates (105). Notably, greater
visceral and liver fat accumulation, regardless of body
weight, have been reported in individuals consuming
daily amounts of SSB (105–107), suggesting a mecha-
nistic pathway linking SSB consumption to abdominal
obesity and cardiometabolic risk factors. In response
to the growing concerns of added sugars on the
escalating obesity rates, the AHA and the 2015 Dietary
Guidelines Advisory Committee have recommended
reducing added sugar intake to <10% of total caloric
intake (88) or consume #9 teaspoons per day (or 150
calories per day) in men and #5 to 6 teaspoons per
day (or 100 calories per day) in women (108).
It is important to note, however, that the assertion
of added sugars in obesity continues to be debated, as
evidence for this association has primarily been sup-
ported by epidemiological and animal studies (109).
Whether this association is causal to the development
of obesity remains to be proven in randomized con-
trol studies (110). Arguably, eating more or less of any
1 food or nutrient may change the total amount of
energy consumed, but the magnitude of this effect
may vary, depending on what else is consumed in the
same meal (111). In the context of SSB consumption,
which is linked to poor overall dietary quality (105),
there are notable confounding dietary characteristics,including the Westernized diet, reliance on processed
foods, and increased eating behaviors out of the
home, not to mention lifestyle behaviors, such as
smoking and a sedentary lifestyle. Coincidently,
eating outside the home and take-away meals and
snacks have independently been associated with
higher energy intakes, increased portion sizes, long-
term weight gain, and a higher risk of obesity (105).
In this regard, targeting SSB, or other dietary metrics
(e.g., fat, calories, carbohydrates), may elicit diver-
gent relationships with long-term weight gain and
thus may not accurately identify how specific dietary
factors influence obesity (87,94). Given that diet
quality presumably affects energy intake (i.e., total
calories), aggregate changes in dietary metrics that
contribute to an overall improved dietary pattern re-
mains to be a key dietary priority for obesity pre-
vention, treatment, and cardiometabolic health (105).
Also, if PA and exercise levels are high, the impor-
tance of dietary GI and sugar contents may be
considerably lessened.
Community prevent ion . Success in reducing
obesity risk through lifestyle and behavioral modifi-
cation has been demonstrated in numerous clinical
intervention trials (90,112,113). However, utilization
of structured protocols have limited the generaliz-
ability of clinical findings to “real-world” settings,
and overall, sustainability of lifestyle modification
efforts outside “investigator-controlled” conditions
has yet to be proven. Leveraging community input in
clinical studies may be the key to ensuring successful
implementation, dissemination, and translation of
evidence-based clinical approaches to broader, more
diverse, vulnerable populations. This notion of part-
nering researchers with multiple stakeholders,
including community members who live with the
problem being investigated, are foundational to
community-based participatory research (113). The
premise of meaningful involvement by members of a
community has recently been woven into multilevel
cross-disciplinary health paradigms that aim to link
community prevention efforts with clinical services.
Integrated partnerships between clinical research
and the community have offered both progress and
promise to obesity prevention research. Most notable
of these “clinic-to-community” strategies has been
the translation of the landmark national Diabetes
Prevention Program to various community settings,
including the Young Men’s Christian Association
(114), churches (115), local health care facilities (116),
underserved communities (117), and on American
Indian reservations in the United States (118).
Collectively, lifestyle protocols modeled after the
Diabetes Prevention Program have shown success in
J A C C V O L . 7 2 , N O . 1 3 , 2 0 1 8 Lavie et al.
S E P T E M B E R 2 5 , 2 0 1 8 : 1 5 0 6 – 3 1 Healthy Weight and Obesity
1519improving various obesity and cardiometabolic met-
rics, with evidence showing sustained improvements
at least 12 months after intervention completion
(119,120).
More system-wide approaches that are likely to
cripple the current obesity epidemic have been her-
alded by larger foundations (e.g., Kaiser Family
Foundation, Robert Wood Johnson Foundation, Cal-
ifornia Endowment, and W. K. Kellogg Foundation)
(121). A core focus of these programs has been to
implement more sustainable, policy-, system-, and
environmental-wide interventions that transform
local environments and remove barriers (environ-
mental and social) that may otherwise hinder indi-
vidual health behavior decision making. Many of
these funded programs have successfully demon-
strated that changes in community environments
(i.e., creating walkable and safe environments and
more green space; increasing affordability, proximity,
and availability of nutritious foods; and increasing
access to health services and wellness programs in
schools) can lead to substantive, desirable, and sus-
tainable public health outcomes (121,122). More
exemplar obesity prevention strategies implemented
by the Centers for Disease Control’s Communities
Putting Prevention to Work initiatives have elicited a
greater obesity reduction affect at the community-
and state-wide levels, specifically by targeting the
community environment (i.e., where an individual
lives), and by modifying multiple contexts within the
community environment that directly affect many
individuals (121). The overall effect size and long-
term sustainability of these policy-, system-, and
environmental-wide initiatives to reduce obesity in
various community settings has yet to be determined
and will likely vary by community factors. Nonethe-
less, leveraging cross-collaborations among commu-
nity members, health care systems, policy makers,
and other environmental stakeholders appears to be
essential to maximize the future investment in
obesity prevention and to facilitate more timely im-
provements in the health of populations (123).
Soc ieta l /author i ta t ive . In the task of obesity pre-
vention, efforts have been (strategically) hurdled by
the debate of responsibility, and more specifically,
whether obesity truly should be accepted as an indi-
vidual responsibility or an environmental/public lia-
bility (124,125). Consequently, discussions on obesity
prevention strategies have been propelled into the
political arena (110,124,125). The views of personal
responsibility, for example, stem from the belief that
obesity is caused by an individual’s irresponsibility to
avoid unhealthy lifestyle behaviors (e.g., diet and
inactivity, sedentariness) and is therefore premisedon individual’s choice to practice sensible dietary and
lifestyle practices. Generally, personal responsibility
patrons view any form of government interference as
being intrusive, demanding, and paternalistic, in
other words, a clear obtrusion to their first amend-
ment rights and freedom of choice (124,125). In-
dividuals who align with this view favor industry to
tackle the perceived problems of obesity (124). Coin-
cidently, these arguments represent a disturbing echo
of the vices used by tobacco industry, which coined
personal responsibility as their first line of defense
against regulation (125). In response to what can only
be seen as successful campaigning, the government
has taken on more of a supportive versus reactive role
by pushing solutions that are viewed as “laissez faire”
in nature; that is, developing sanctioned nutrition
education and encouraging PA/exercise through pro-
paganda. As is evident with our nation’s current
obesity statistics, such conservative measures have
yet to show any significant affect in slowing down
obesity in this country.
The notion that obesity is both caused and exac-
erbated by our obesogenic environment falls in line
with those advocating for environmental/govern-
mental responsibility. Environmental responsibility
proponents, therefore, encourage regulatory re-
sponses by government (125). Through much perse-
verance, local- and state-wide progress in increasing
obesity awareness, detoxifying our environment, and
“healthifying” the general public has been made by
lobbying activists (e.g., Obesity Society, Center for
Science in the Public Interest, American Diabetes
Association, AHA, and Academy of Nutrition and Di-
etetics). Although some initiatives, such as calorie/
nutrition menu labeling and regulation of food in-
gredients (i.e., transfats in restaurants), have shown
resiliency against industry and public opposition,
other, more controversial, strategies, such as curtail-
ing food advertisements (particularly those targeting
youth) or SSB taxation, have been limited to regional
successes, but with the potential to reach national
influence. Regardless of whether successes have been
long-term or short-lived, each of these public health
initiatives has been instrumental in raising the
salience of obesity as a national threat to our society.
However, if government is going to intervene, in-
sights can be obtained from the North Karelia Project
experience (126,127). In the 1960s and 1970s, CVD
mortality in Finland was perhaps the highest in the
world. In 1972, the North Karelia Project was estab-
lished to reduce the extremely high CHD mortality
through behavioral change and reductions in the
major CVD risk factors among the whole population of
North Karelia, targeting smoking, cholesterol, and
TABLE 3 Recommendations for Physical Activity
 Maintaining and improving health: 150 min/week
 Prevention of weight gain: 150 to 250 min/week
 Promote clinically significant weight loss: 225 to 420 min/week
 Prevention of weight gain after weight loss: 200 to 300 min/week
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mortality (127). Therefore, some of the governmental
aspects of the success of this type of program could
also be transferred to obese in the United States and
worldwide.
WHERE TO GO FROM HERE?
With differing opinions regarding responsibility, it is
not surprising that discussions on obesity solutions
have inspired divergent policy recommendations
(125). The primary question regarding how our legis-
lation will respond to the obesity problem remains
unanswered. Treating obesity through medical in-
terventions (i.e., surgical to pharmaceutical) has
significantly escalated in recent years, whereas
obesity prevention, the most cost-effective, common-
sense approach to reversing the inevitable obesity
forecast of our nation and globally (128) has remained
lost amid the politics of obesity. Clearly, stronger
initiatives are needed to affect the world’s discerning
obesity trajectories. For example, any proposed stra-
tegies that address the U.S. obesity crisis will require
common ground between public health lobbyists;
however, creating approaches that provide personal
and public collective benefit remains a challenge.
Leveraging personal responsibility by “rehabbing” all
sectors of our environment (i.e., school programs,
food industry and marketing practices, food taxation)
has been a central theme in proposals suggested by
special interest groups, with the premise being that
creating these healthier “defaults” in our environ-
ment will help foster more responsible decision
making, bridging the divide between individualistic
and environmental views shared by policy makers
(125). Solutions of this manner will undoubtedly
depend on successful public advocacy (124) and more
judicious authority by all government sectors to bet-
ter regulate individual behavior and promote public
health (110,125). Ultimately, reconciling the frontier
of our obesity crisis will require a greater commit-
ment from individuals and environmental policy
makers and lobbyists (i.e., government and food in-
dustry) to create a proactive culture of health and
wellness that aspires to prevent chronic disease
rather than treating it. Certainly, global efforts toincrease PA/exercise and CRF across the life span
would go a long way to promote these efforts (129).
Spec ifics of PA/exerc i se t ra in ing . As reviewed
earlier, as well as elsewhere in this Seminar Series,
there is substantial evidence that low PA is a signifi-
cant, possibly the most significant, contributor to
weight gain and obesity (68–70). Certainly, PA and
exercise training is better to prevent weight gain than
it is to promote marked levels of weight reduction in
more severe obesity (130). However, PA/exercise is
critical to prevent further weight gain in overweight/
obese individuals and to prevent overweight in-
dividuals from becoming obese and to prevent mildly
obese from progressing to severe and morbid levels of
obesity. Researchers have speculated on the amount
of PA necessary to prevent weight gain, promote
clinical significant weight loss, and to prevent weight
regain after successful weight loss (130). The Amer-
ican College of Sports Medicine recommends 150 to
250 min/week of moderate to vigorous PA, with an
energy equivalent of 1,200 to 2,000 kcal/week to
prevent weight gain. To induce weight loss in over-
weight and obese patients, the requirement is
considerably higher, with prevention of weight gain
after successful weight loss being in between
(Table 3). Although many weight loss studies defined
clinically significant weight loss as $5%, we have
demonstrated considerable improvements in insulin
resistance with modest weight loss (3% to 4.9%) with
exercise training, which is similar to that obtained
with more significant weight loss and may represent a
reasonable initial weight loss target with exercise
training (131). Clearly, improvements in CRF with PA
and exercise training are extremely important and
may be more important than weight loss per se, as
considerable evidence suggests that fitness may be
more important than fatness for predicting prognosis
(47,113).
SEDENTARY BEHAVIORS. Concurrent with efforts to
increase PA engagement, targeting excessive seden-
tary behavior has been a focal point of obesity and
chronic disease prevention strategies (132). However,
sedentariness represents a construct distinct from
physical inactivity (57) and is therefore considered to
be a unique determinant of health consequences
(133). Sedentary behavior specifically refers to time
spent in a sitting, reclining, or lying down position
(e.g., watching television, playing computer games,
driving a car, sitting, or reading) during waking hours,
resulting in an energy expenditure of #1.5 metabolic
equivalents (METs) (71,134). Accordingly, the amount
of time spent in sedentary behaviors is associated
with increased risk of weight gain (135) and is
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obesity, a variety of other chronic conditions (135),
and ultimately higher mortality (136); the risks asso-
ciated with obesity are independent of body weight,
PA, and eating behaviors (137). The highest risk of
obesity and comorbidities are among inactive in-
dividuals with higher levels of sedentariness (132)
and are thus in greatest need of lifestyle in-
terventions. Notwithstanding, even individuals who
are otherwise physically active but engage in pro-
longed periods of sedentary behavior are subject to
adverse cardiometabolic alterations (132,137). Physi-
ologically, prolonged sitting results in the loss of cu-
mulative energy expended during contractions from
the large skeletal muscle groups (e.g., legs, back, and
trunk) during the waking hours of the day (135),
contributing to the greater propensity to become
overweight or obese. A shift of 2 h/day from light-
intensity behaviors (i.e., 2.5 METs) to sedentary be-
haviors (i.e., 1.5 METs) is equivalent to 2 MET-h/day
(or 2 kcal/kg/day of energy conserved). In this
context, it can be estimated that for someone with a
normal body weight and a resting energy expenditure
of 67 kcal/h, this increase in sedentary behavior
would equate to a 134 kcal/day surplus, equivalent to
the amount of energy that is expended during a 30-
min episode of brisk walking (3.5 METs).
Conversely, in an obese individual, an additional 2 h/
day spent sitting is approximately equal to 350 kcal/
day surplus (138). This example further highlights the
importance of promoting PA in obese individuals.
Additionally, a study by Ekelund et al. (73) showed
that high PA almost completely abolished the adverse
effects of prolonged sitting on all-cause mortality.
Given our contemporary society, and consistent
with epidemiological publications, it is apparent that
both too little exercise and general PA, coupled with
too much sitting, propel weight gain and presumably
interfere with weight loss efforts. On average, for a
person weighting 72 kg (w158 pounds), every minute
of sedentary behavior replaced with light PA would
presumably equate to an additional 1 kcal expended
(calculated assuming 1.5 vs. 2.3 METs for a person
weighing 72 kg) (139). Hence, in regard to obesity
treatment, advising patients to reduce prolonged
sitting and optimally replace sedentary behavior by
moving a little more (133), weight reduction,
adequate weight management, and importantly,
health improvements are likely, especially among
those with substantial disease burden or risk. In
support, increasing evidence suggests interrupting
sedentary activities with light PA effectively im-
proves various domains of cardiometabolic risk fac-
tors in overweight/obese populations and particularlyin those with dysglycemia (140) or T2DM (141). Like-
wise, replacing even modest doses of sedentary time
(e.g., 10 min) with equal amounts of PA (142) or
interrupting sitting time with 2-min periods of light-
or moderate-intensity walks every 20 min (102) has
been shown to have clinically significant, favorable
effects on BMI and WC, as well as glycosylated he-
moglobin, lipids (142), postprandial glucose, and in-
sulin levels (102,140). Ultimately, the evidence,
though primarily observational in nature, is prom-
ising with regard to reversing health consequences
associated with obesity. In the contention of obesity
treatment, engaging in strategies that break up or
replace sedentary time with modest amounts of light
PA is a prudent, yet feasible approach to promoting
weight reduction and optimizing behavioral lifestyle
therapy compliance over time (139,142).
PHARMACOTHERAPY AND
BARIATRIC SURGERY
Similar to other chronic diseases in which lifestyle
modification alone may not be effective enough to
control symptoms and/or adverse outcomes, phar-
macotherapy and bariatric surgery are 2 evidence-
based treatments that can be used to intensify
therapy for obesity. The goal of using these in-
terventions is to enhance weight loss and improve the
associated comorbid conditions, such as hyperglyce-
mia, hypertension, and dyslipidemia. According to
U.S. Food and Drug Administration, anti-obesity
medications are approved for patients with a
BMI$30 kg/m2 or with a BMI$27 kg/m2 who also have
concomitant obesity-related risk factors or diseases
and for whom dietary and PA therapy has not
been successful. Anti-obesity medications require
the implementation of lifestyle modification as a
foundation for drug action due to the importance of the
drug-behavior interaction, in other words, by pharmaco-
logically modifying the sensation of hunger and/or
satiety, patients must deliberately and consciously alter
their eating behavior for weight loss to occur, thus pro-
ducing a negative energy (calorie) balance.
Among the 6 U.S. Food and Drug Administration–
approved medications used today (Table 4), 5 are
approved for weight loss and maintenance of weight
loss (orlistat, lorcaserin, phentermine/topiramate,
naltrexone sustained release, bupropion sustained
release, and liraglutide), and 1 is approved only for
short-term use (phentermine). Except for orlistat,
which acts peripherally as a competitive gastrointes-
tinal lipase inhibitor, the other 5 medications func-
tion centrally, targeting sites in the appetite center of
the hypothalamus, the nucleus tractus solitarius, or
TABLE 4 Summary of Centrally Acting Anti-Obesity Medications Approved for Long-Term Weight Management
Phentermine–Topiramate Lorcaserin Naltrexone–Bupropion Liraglutide
Mechanism of action Sympathomimetic modulation of gamma-
aminobutyric acid receptors and/or










Mean percentage of weight
loss: drug vs. placebo*
7.8–10.9 vs. 1.2–1.6 4.8–5.8 vs. 3.0–3.6 6.1–6.5 vs. 1.3–1.9 6.2–8.0 vs. 0.2–2.6
Categorical change in 5%
weight loss: drug vs.
placebo*
62.0–66.7 vs. 17.3–21.0 47.2–47.5 vs. 20.3–25.0 48.0–50.5 vs. 16.0–17.1 63.2–81.4 vs. 27.1–48.9
Most common adverse
events
Dry mouth, paresthesias, headache,
insomnia
Headache, dizziness, diarrhea Nausea, GI complaints,
headache, insomnia
Nausea, GI complaints
Dosage and administration Once daily Twice a day or once daily
extended release
2 tablets twice daily Once daily by subcutaneous
injection
*Mean 1-year outcomes from clinical trials.
AMPA ¼ alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; GI ¼ gastrointestinal.
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1522reward centers of the brain. Patients who are
responsive to medication experience various percep-
tions of less hunger, earlier and prolonged satiety,
fewer thoughts of food, and diminished cravings.
Accordingly, patients are better able to adhere to a
calorie-controlled diet.
Excluding phentermine, which was approved in
1959 as a short-term weight loss agent, the other 4
centrally acting medications were approved since
2012 and underwent randomized, placebo-controlled,
double-blind trials for efficacy and safety. A summary
of the medications, weight loss outcomes, and
adverse events is shown in Table 4 (143–150). Inter-
estingly, phentermine, topiramate, naltrexone,
bupropion, and liraglutide have been previously
approved for other indications and should be familiar
to clinicians. When used either in combination or at a
different dose, they are effective as weight loss
agents. In contrast, lorcaserin is a new compound that
was selectively developed as a serotonergic agonist.
Clinical and statistical dose-dependent improve-
ments are seen in intermediate CV and metabolic
outcome measurements that are related to the weight
loss. The selection of which medication to use is
based on several factors, including comorbidities,
drug-drug interactions, side effects, route of delivery,
dosing frequency, and cost. The Endocrine Society’s
guidelines on the Pharmacological Management of
Obesity emphasizes the importance of shared deci-
sion making in the use and selection of agents (151).
Due to its higher risk and cost, bariatric surgery
should be considered for patients with severe obesity
(BMI $40 kg/m2) or those with moderate obesity
(BMI $35 kg/m2) associated with a serious medical
condition, such as diabetes, heart disease, sleepapnea, lipid abnormality, or nonalcoholic fatty liver
disease. According to the AHA/American College of
Cardiology/The Obesity Society guidelines, patients
who are motivated to lose weight and who have not
responded to behavioral treatment with or without
pharmacotherapy with sufficient weight loss to ach-
ieve targeted health outcome goals should be advised
that bariatric surgery may be an appropriate option to
improve health (90).
The 2 most commonly performed procedures are
the laparoscopic sleeve gastroplasty and Roux-en-Y
gastric bypass. The clinical benefits of bariatric sur-
gery in achieving weight loss and alleviating meta-
bolic comorbidities have been attributed largely to
changes in the physiologic responses of gut hor-
mones, bile acid metabolism, the microbiota, and
adipose tissue metabolism. Mean weight loss at 2 to 3
years following a surgical procedure ranges from 20%
to 34% of initial body weight, depending on the pro-
cedure. Significant improvement in CVD outcomes
such as myocardial infarction, stroke, CVD risk and
events, and mortality have been reported from
matched controlled studies (152,153). One of the most
significant clinical outcomes is the role of bariatric
surgery in the treatment of patients with T2DM,
where bariatric/metabolic surgery has demonstrated
superior glycemic control in patients with T2DM
compared with various medical and lifestyle in-
terventions (154,155). Based on this data, the 2018
Standards of Care for Diabetes from the American
Diabetes Association includes bariatric surgery in the
treatment algorithm for T2DM. All surgical patients
should participate in post-operative programs that
support lifestyle modification because obesity is
considered a chronic disease.
TABLE 5 Learning Objectives for Behavioral Sciences Knowledge and Skills Development During Undergraduate Medical Training
Domains Learning Objectives
Knowledge Describe counseling steps that foster behavioral change.
Describe a patient-centered approach and core concepts of major behavior change theories.
Recognize the expertise of the behavioral counselor and distinguish health professionals who have expertise in supporting
specific types of lifestyle behavioral change.
Skills Assess lifestyle behaviors and patients’ confidence and readiness to make changes.
Demonstrate effective patient-centered communication skills to help the patient set behavior change goals and establish a plan.
Use appropriate behavior change techniques, such as goal setting, self-monitoring, and reinforcement, to support patients in
making healthy lifestyle changes.
Appropriately adapt counseling to patients’ age, sex, race or ethnicity, culture, and preferences.
Refer to a behavioral counselor or other health care professionals with behavioral expertise when appropriate.
Reproduced with permission from Hivert et al. (156).
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Health care in the United States as well as in a ma-
jority of countries around the world is undergoing a
needed major paradigm shift that entails recognition
of 5 salient points. 1) The leading global health care
concern is the staggering negative impact chronic
disease, both the current crisis as well as future pro-
jections, has on health outcome and the economy. 2)
Obesity is a leading risk factor for the development of
chronic disease. 3) Moving forward, there needs to be
a much greater focus on the prevention of chronicTABLE 6 Learning Objectives for Nutritional Assessment and Counse
Domains
Nutrition assessment Describe health benefits of recommended diet
for the prevention and treatment of divers
Assess dietary behaviors and evaluate patients
Recognize the need for detailed nutritional as
nutritional expertise when appropriate.
Nutrition diagnosis Describe pathogenesis of nutrition-related dia
Diagnose nutrition-related problems and prior
Recognize and use diagnostic labels for docum
Communicate effectively with RD, including un
and symptoms” statements commonly use
Nutrition intervention Assess patients’ confidence and readiness to c
practices.
Counsel patients on the benefits of evidenced-
of diverse medical conditions.
Use appropriate behavioral skills and tools to
Demonstrate effective communication skills wi
Appropriately counsel patients according to ag
Recognize the need and appropriate timing for
with the intent of modifying a nutrition-re
Support the implementation of the nutrition in
Nutrition monitoring and
evaluation
Facilitate goal setting and periodic evaluation
Support behavioral changes by advising the us
Evaluate the health effects of nutrition modifi
Reproduced with permission from Hivert et al. (156).
RD ¼ registered dietician.disease, ideally before primary risk factors, including
excess body mass, manifest. 4) HLM, which includes
PA and generally moving more, healthy nutrition,
healthy body weight, and not smoking, is vital to the
prevention as well as treatment of chronic disease. 5)
To shift toward a much greater focus on chronic dis-
ease prevention and the needed increase in the de-
livery of HLM, the way we train health care
professionals must evolve.
Recently, the AHA published a scientific statement
titled “Medical Training to Achieve Competency in
Lifestyle Counseling: An Essential Foundation forling During Undergraduate Medical Training
Learning Objectives
ary patterns and current dietary guidelines for maintenance of health and
e medical conditions.
’ habitual food intake.
sessment and referral to RD and other health care professionals with
gnoses.
itize them.
entation in patients’ medical records.
derstanding the information conveyed by the “problem, etiology, signs,
d by RD.
hange toward a healthy lifestyle behavior that includes good nutritional
based recommended nutrition practices for the prevention and treatment
help patients initiate and maintain good nutritional practices.
th patients and other health care professionals with nutritional expertise.
e, sex, race or ethnicity, culture, and other personal characteristics.
referral to RD or other health care professionals with nutrition expertise
lated behavior.
tervention with members of the health care team.
of dietary recommendations.
e of monitoring tools in achieving nutrition-related goals.
cations made by patients.
TABLE 7 Learning Objectives for PA and Exercise Assessment and Counseling During Undergraduate Medical Training
Domains Learning Objectives
PA assessment Describe the normal physiological responses to an acute bout of exercise and adaptations to aerobic and resistance
exercise training.
Describe health benefits of PA for health maintenance and in diverse medical conditions, as well as recommended
guidelines for an active lifestyle.
Assess PA behaviors using the appropriate tools for patients who are healthy, have controlled disease, or are living with
a disability.
Recognize the need for additional assessments such as symptom-limited exercise testing and refer to appropriate
health care professionals or clinical settings.
PA and exercise
prescription
Recognize individuals who do not meet current PA recommendations.
Develop a safe PA or exercise prescription for apparently healthy people, those at increased risk for developing a
chronic noncommunicable disease, and patients with specific medical conditions.






Assess patients’ confidence and readiness to change toward a healthy lifestyle behavior as it relates to PA and exercise.
Counsel patients on the benefits of PA in health maintenance and for prevention and treatment of specific medical
conditions.
Use appropriate behavioral tools and skills to support patients to initiate or maintain a PA plan.
Demonstrate effective patient communication skills with regard to PA and exercise assessment and counseling in all
clinical settings.
Appropriately counsel patients according to age, sex, race or ethnicity, culture, and other personal characteristics.
Recognize the need for individualized or supervised PA programs when referring a patient to appropriate health care
professionals with PA or exercise expertise.
Support the implementation of the PA intervention in close collaboration with other members of the health care team.
Use behavioral strategies to maintain an active lifestyle, including monitoring, goal setting, and periodic reassessment.
Evaluate the health effects of PA modifications with patients and reinforce or adjust the plan accordingly.
Physician’s
personal health
Recognize the importance of an active lifestyle for his or her own quality of life, professional balance, and as a role
model for patients.
Reproduced with permission from Hivert et al. (156).
PA ¼ physical activity.
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and Other Chronic Medical Conditions” (156). This
statement, focused on medical education, recognizes
HLM is not frequently delivered in current practice;
z34% of physicians reporting the performance of
lifestyle counseling to their patients during office
visits. Interestingly, patients report an even lower
frequency of receiving HLM; as an example, obese
patients reported their primary care providers pro-
vided counseling on PA and nutrition during z20%
and z25% of office visits, respectively (90). This is in
contrast to current overweight and obesity guidelines
affording lifestyle counseling, primary of which are
PA and healthy nutrition counseling, a Class A, Level
1 recommendation (90). A primary mechanism for the
current low practice of HLM by physicians is a lack of
training in this critical area while receiving their
medical education; currently very few medical
schools have a well-developed HLM curriculum
(156,157). Medical students not made aware of the
importance of a healthy lifestyle for the prevention
and treatment of chronic disease, or who are not
prepared to deliver HLM, have a low likelihood of
integrating this important intervention into theirmedical practice on graduation. Data indicate that
when medical training includes content on HLM in a
meaningful way, students both comprehend its
importance to chronic disease prevention and man-
agement (158). The AHA, American College of Cardi-
ology Foundation, American College of Physicians,
and the Institute of Medicine have all called for
stronger HLM curricula in medical schools
(156,159,160). The recent AHA statement on medical
training for HLM proposed behavioral science, nutri-
tion, and PA competencies during undergraduate
medical training (Tables 5 to 7). The authors of this
review wholeheartedly support a strong HLM curric-
ulum in all medical schools that incorporate the
competencies listed in Tables 5 to 8.
Although physicians must play a leading role in
delivering HLM, all health professionals (e.g., nurses,
pharmacists, dentists, physical and occupational
therapists) can and should play important roles. Pa-
tients in all practice settings, from primary care to
specialized clinics focused on chronic disease man-
agement (e.g., cardiology, pulmonology, endocri-
nology) should receive a consistent HLM message.
Unfortunately, akin to medical school curricula, other
TABLE 8 Healthy Living Practitioner Graduate Certificate Curriculum





 Describe the incidence and prevalence of behaviors that lead to disease states and key
health measures and how they begin early in the life course.
 Describe the relationship between LS7 score and other evidence-based risk calculators
(e.g., Framingham, ASCVD risk calculator, Reynolds) and chronic disease risk.
 Describe the intersection between unhealthy behaviors, social determinants of health,
policy, systems, and environment on population health outcomes and economic
ramifications.
 Describe policy initiatives centered on improving healthy living characteristics and other




 Read as a critical thinker to better translate nutrition and exercise science, both regulated
and nonregulated (e.g., supplements for general health and exercise) for a wide and varied
audience.
 Understand the role of pragmatism to support a 2-way health dialogue.
 Appreciate the distinction between scientific and anecdotal evidence as it relates to health
and wellness and how this distinction influences the 2-way health dialogue.
 Appreciate that there are many forms of literacy that lack hierarchy but can be orchestrated




 Be able to use perform a basic health screening assessment, using evidence-based tools, to
ascertain the risk for or potential presence of 1 or more chronic diseases.
 Become familiar with current evidence-based risk prediction tools (e.g., LS7, Framingham,
ASCVD risk calculator, Reynolds).
1
Nutrition for Healthy Living  Understand basic principles of nutrition throughout the life cycle (from embryo to elderly
person).
 Understand basic concepts of nutrition and chronic disease, for both deficiency and degen-
erative diseases (arthritis, osteoporosis—non-trauma-related).
 Be able to perform a basic nutritional assessment.
 Be able to provide basic guidance on healthy nutrition.







 Understand basic principles of exercise and physical activity in health and disease states.
 Be able to interpret exercise and physical activity assessments.




 Understand challenges surrounding adoption of a healthy living behaviors.
 Be able to employ basic behavioral counseling strategies focused on improving LS7 scores,
mental health, and well-being.
 Be able to employ basic behavioral counseling strategies to those facing socioeconomic
challenges (e.g., food stamps, government assistance).
2
Use of Technology for
Healthy Living
 Understand basic principles of health information systems and informatics with implica-
tions for tracking and managing LS7 characteristics.
 Be able to effectively utilize technology (e.g., web, social media, mobile applications,
wearable devices) to track LS7 characteristics and enhance healthy living interventions.
 Understand the role of technology in a citizen science approach (e.g., taking photos of built
environment—how does the environment promote/hinder healthy living).
2
Healthy Living Seminar  Through an interprofessional group project, develop and present a healthy living program
proposal in a broad array of settings and environments (e.g., community, workplace, school




Healthy Living Practicum  Participate in the development and/or implementation of a healthy living program in a
broad array of settings and environments (e.g., community, workplace, school system,
health care organization).
3
Reproduced with permission from Hivert et al. (157).
ASCVD ¼ atherosclerotic cardiovascular disease; LS7 ¼ Life’s Simple 7.
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1525health professions commonly do not provide suffi-
cient training in HLM (161,162). To address this issue,
Hivert et al. (157) and Arena et al. (163) recently pro-
posed the Healthy Living Practitioner (HLP) graduatecertificate program. This 22-credit program is a
“stackable credential” meant to be taken as an elec-
tive sequence in parallel to a student’s health pro-
fession training; students in any discipline are
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1526eligible for this program, thereby embracing an
interprofessional education model. The University of
Illinois at Chicago launched the program in the fall of
2017 (164). The University of Tasmania in Australia
and University of Belgrade in Serbia are both pre-
paring to launch the HLP program in the next 1 to 2
years. Expansion to other academic institutions
globally will follow. AHA has trademarked the HLP
brand, ensuring a uniform training model with high
academic rigor. Table 8 lists the HLP graduate certif-
icate program. This model has the potential to train a
large number of health professions across all disci-
plines, creating a health care workforce proficient in
the delivery of HLM.
The published reports indicate lifestyle counseling
by health professionals can result in significant and
clinically meaningful improvements in behaviors and
health profile, including weight loss in those who are
overweight or obese (165–168). Most research has
examined the efficacy of physicians and nurses in
lifestyle counseling and subsequent outcomes.
Fewer studies have been performed to suggest the
potentially important role of other health pro-
fessionals, including pharmacists (169–172), dentists
(162,173), physical therapists (174), and occupational
therapists (161). Currently, the publications on the
benefits of lifestyle interventions delivered by phar-
macists appear to be most robust and promising (169–
171). Moreover, using a pharmacy as a community-
based platform to deliver HLM holds promise. In a
rural Australian community, Kellow (175) demon-
strated a lifestyle program that was provided to 40
individuals under 50 years of age with chronic dis-
ease risk factors resulted in significant weight loss as
well as a significant increase in fruit and vegetable
consumption and PA. The year-long program con-
sisted of free nutritional counseling (after hours) by a
dietician, a pharmacist-led medication review, and a
gym membership, as well as the opportunity to
participate in cooking classes and supermarket tours.
Overall, research examining the benefits of a broader
array of health professionals participating in HLM is
currently in its initial stages and must expand to
determine optimal roles, messaging, and in-
terventions. Moreover, it appears that lack of
training in the delivery of HLM is a barrier for health
professionals to appropriately implement HLM into
their practice (161,162), an issue that can and should
be addressed by changes in academic preparation
across all disciplines.
Of significant note, it appears that intensive life-
style counseling, entailing more contact with health
professionals proficient in delivering HLM in anindividualized and group format, goal setting, and
such, is needed for more significant and lasting im-
provements (176–178). In a systematic review and
meta-analysis of “Lifestyle Weight-Loss Intervention
Outcomes in Overweight and Obese Adults With Type
2 Diabetes,” Franz et al. (178) concluded that weight
loss >5% was required for clinically significant im-
provements in glycosylated hemoglobin, as well as
lipids and blood pressure. To achieve this weight loss
goal, it was concluded that intense lifestyle in-
terventions, such as energy restriction, a regular ex-
ercise program, and frequent contact with a qualified
health professional was needed (178). Given the
frequent need for intensive lifestyle interventions in
those who are at high risk for or already diagnosed
with 1 or more chronic diseases, often the case in
those individuals who are overweight or obese, it will
be important to train physicians, nurses, and other
health professionals, who serve as the initial point of
patient contact, on when to refer individuals for
intensive lifestyle counseling to optimize long-term
compliance and health outcomes.
FUTURE DIRECTIONS AND CONCLUSIONS
Clearly, better long-term studies are needed to
determine optimal weight in various groups of pa-
tients, especially studies that adequately control for
PA, exercise, and CRF. Also, studies are needed that
assess the impact of various weight loss strategies on
the development of CVD and other chronic diseases,
as well as the cost-effectiveness of these strategies.
Additionally, weight loss studies are needed in both
primary and secondary prevention, including assess-
ing clinical events and survival in patients with CHD
in both HF with preserved and reduced ejection
fraction. Finally, the impact of various programs in
school children and adults, including taxing certain
food items, such as SSB, by various governmental
programs, needs to be determined. Clearly, a multi-
modality approach and intervention, as reviewed
here (Central Illustration), will be required to reduce
the devastating consequences of progressive obesity
in our society and, especially, for the prevention and
treatment of CVD.
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